{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:45:35Z","timestamp":1792266335145,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-026-06303-0","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:10:58Z","timestamp":1792213858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tocilizumab for active rheumatoid arthritis in a patient with concomitant primary biliary cholangitis: a case based review"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8210-0715","authenticated-orcid":false,"given":"Goran","family":"\u0160ukara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-0821","authenticated-orcid":false,"given":"Petra","family":"Dinjar Kujund\u017ei\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5789-1869","authenticated-orcid":false,"given":"Anita","family":"Madir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3276-0971","authenticated-orcid":false,"given":"Ivana","family":"Pite\u0161a Ko\u0161uti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9190-7828","authenticated-orcid":false,"given":"Jo\u0161ko","family":"Mitrovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"6303_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.ard.2026.01.023","volume":"85","author":"JS Smolen","year":"2026","unstructured":"Smolen JS, Edwards CJ, Konzett V et al (2026) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis 85:991\u20131009. https:\/\/doi.org\/10.1016\/j.ard.2026.01.023","journal-title":"Ann Rheum Dis"},{"key":"6303_CR2","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/hep.32117","volume":"75","author":"KD Lindor","year":"2022","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M (2022) Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology 75:1012\u20131013. https:\/\/doi.org\/10.1002\/hep.32117","journal-title":"Hepatology"},{"key":"6303_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","volume":"404","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Ma X, Takahashi A, Vierling JM (2024) Primary biliary cholangitis. Lancet 404:1053\u20131066. https:\/\/doi.org\/10.1016\/S0140-6736(24)01303-5","journal-title":"Lancet"},{"key":"6303_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073848","volume":"25","author":"IR Mihai","year":"2024","unstructured":"Mihai IR, Rezus C, Burlui MA, Cardoneanu A, Macovei LA, Richter P, Bratoiu I, Rezus E (2024) Autoimmune liver diseases and rheumatoid arthritis\u2014is there an etiopathogenic link? Int J Mol Sci 25:3848. https:\/\/doi.org\/10.3390\/ijms25073848","journal-title":"Int J Mol Sci"},{"key":"6303_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/391567","author":"DS Smyk","year":"2012","unstructured":"Smyk DS, Bogdanos DP, Mytilinaiou MG, Burroughs AK, Rigopoulou EI (2012) Rheumatoid arthritis and primary biliary cirrhosis: cause, consequence, or coincidence? Arthritis (Basel). https:\/\/doi.org\/10.1155\/2012\/391567","journal-title":"Arthritis (Basel)"},{"key":"6303_CR6","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","volume":"115","author":"CF Murillo Perez","year":"2020","unstructured":"Murillo Perez CF, Harms MH, Lindor KD et al (2020) Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol 115:1066\u20131074. https:\/\/doi.org\/10.14309\/ajg.0000000000000557","journal-title":"Am J Gastroenterol"},{"key":"6303_CR7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C et al (2024) Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med 390:795\u2013805. https:\/\/doi.org\/10.1056\/NEJMoa2306185","journal-title":"N Engl J Med"},{"key":"6303_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ et al (2024) A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med 390:783\u2013794. https:\/\/doi.org\/10.1056\/NEJMoa2312100","journal-title":"N Engl J Med"},{"key":"6303_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/HEP.0000000000001465","volume":"83","author":"A Martins","year":"2026","unstructured":"Martins A, Khakoo NS, Reddy A et al (2026) Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: a systematic review and network meta-analysis. Hepatology 83:721\u2013734. https:\/\/doi.org\/10.1097\/HEP.0000000000001465","journal-title":"Hepatology"},{"key":"6303_CR10","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/HEP.0000000000001166","volume":"82","author":"C Levy","year":"2025","unstructured":"Levy C, Bowlus CL (2025) Primary biliary cholangitis: personalizing second-line therapies. Hepatology 82:895\u2013910. https:\/\/doi.org\/10.1097\/HEP.0000000000001166","journal-title":"Hepatology"},{"key":"6303_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40744-020-00219-2","volume":"7","author":"EG Favalli","year":"2020","unstructured":"Favalli EG (2020) Understanding the role of interleukin-6 (IL-6) in the joint and beyond: a comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis. Rheumatol Ther 7:473\u2013516. https:\/\/doi.org\/10.1007\/s40744-020-00219-2","journal-title":"Rheumatol Ther"},{"key":"6303_CR12","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/art.40176","volume":"69","author":"MC Genovese","year":"2017","unstructured":"Genovese MC, Kremer JM, van Vollenhoven RF, Alten R, Scali JJ, Kelman A, Dimonaco S, Brockwell L (2017) Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis. Arthritis Rheumatol 69:1751\u20131761. https:\/\/doi.org\/10.1002\/art.40176","journal-title":"Arthritis Rheumatol"},{"key":"6303_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/386328","volume":"2014","author":"E Saito","year":"2014","unstructured":"Saito E, Sato S, Nogi S et al (2014) A case of rheumatoid arthritis and limited systemic sclerosis overlap successfully treated with tocilizumab for arthritis and concomitant generalized lymphadenopathy and primary biliary cirrhosis. Case Rep Rheumatol 2014:386328. https:\/\/doi.org\/10.1155\/2014\/386328","journal-title":"Case Rep Rheumatol"},{"key":"6303_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.reuma.2020.04.014","volume":"17","author":"S Azevedo","year":"2021","unstructured":"Azevedo S, Sousa-Neves J, Ramos Rodrigues J, Peixoto D, Tavares-Costa J, Teixeira F (2021) Remission of rheumatoid arthritis and primary biliary cholangitis after treatment with tocilizumab. Reumatol Clin 17:364\u2013365. https:\/\/doi.org\/10.1016\/j.reuma.2020.04.014","journal-title":"Reumatol Clin"},{"key":"6303_CR15","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e225","volume":"39","author":"IC Benlidayi","year":"2024","unstructured":"Benlidayi IC, Gupta L (2024) Case-based review standards (CABARET): considerations for authors, reviewers, and editors. J Korean Med Sci 39:e225. https:\/\/doi.org\/10.3346\/jkms.2024.39.e225","journal-title":"J Korean Med Sci"},{"key":"6303_CR16","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR et al (2021) 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 73:1108\u20131123. https:\/\/doi.org\/10.1002\/art.41752","journal-title":"Arthritis Rheumatol"},{"key":"6303_CR17","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay C, Emery P, van Vollenhoven R et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381:1541\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(13)60250-0","journal-title":"Lancet"},{"key":"6303_CR18","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00296-022-05143-y","volume":"42","author":"T Zeki\u0107","year":"2022","unstructured":"Zeki\u0107 T, Stani\u0107 Beni\u0107 M, Radi\u0107 M (2022) Treatment of rheumatoid arthritis with conventional, targeted and biological disease-modifying antirheumatic drugs in the setting of liver injury and non-alcoholic fatty liver disease. Rheumatol Int 42:1665\u20131679. https:\/\/doi.org\/10.1007\/s00296-022-05143-y","journal-title":"Rheumatol Int"},{"key":"6303_CR19","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00296-011-2060-2","volume":"32","author":"T Nagashima","year":"2012","unstructured":"Nagashima T, Maruyama A, Kamata Y, Minota S (2012) Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection. Rheumatol Int 32:2231\u20132232. https:\/\/doi.org\/10.1007\/s00296-011-2060-2","journal-title":"Rheumatol Int"},{"key":"6303_CR20","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s00296-015-3366-2","volume":"35","author":"D Dimopoulou","year":"2015","unstructured":"Dimopoulou D, Dimitroulas T, Akriviadis E, Garyfallos A (2015) Infliximab as a treatment option for patients with rheumatoid arthritis and primary biliary cirrhosis. Rheumatol Int 35:1913\u20131916. https:\/\/doi.org\/10.1007\/s00296-015-3366-2","journal-title":"Rheumatol Int"},{"key":"6303_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103289","volume":"148","author":"Q Qian","year":"2024","unstructured":"Qian Q, Wu Y, Cui N et al (2024) Epidemiologic and genetic associations between primary biliary cholangitis and extrahepatic rheumatic diseases. J Autoimmun 148:103289. https:\/\/doi.org\/10.1016\/j.jaut.2024.103289","journal-title":"J Autoimmun"},{"key":"6303_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298225","volume":"19","author":"Z Liu","year":"2024","unstructured":"Liu Z, Shao Y, Duan X (2024) Genetic link between primary biliary cholangitis and connective tissue diseases in European populations: a two-sample Mendelian randomization study. PLoS ONE 19:e0298225. https:\/\/doi.org\/10.1371\/journal.pone.0298225","journal-title":"PLoS ONE"},{"key":"6303_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152142","volume":"58","author":"J Fan","year":"2023","unstructured":"Fan J, Jiang T, He D (2023) Genetic link between rheumatoid arthritis and autoimmune liver diseases: a two-sample Mendelian randomization study. Semin Arthritis Rheum 58:152142. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152142","journal-title":"Semin Arthritis Rheum"},{"key":"6303_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jaut.2009.09.010","volume":"33","author":"V Barak","year":"2009","unstructured":"Barak V, Selmi C, Schlesinger M, Blank M, Agmon-Levin N, Kalickman I, Gershwin ME, Shoenfeld Y (2009) Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J Autoimmun 33:178\u2013182. https:\/\/doi.org\/10.1016\/j.jaut.2009.09.010","journal-title":"J Autoimmun"},{"key":"6303_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40744-018-0130-6","volume":"5","author":"B Haraoui","year":"2018","unstructured":"Haraoui B, Jamal S, Ahluwalia V, Fung D, Manchanda T, Khraishi M (2018) Real-world tocilizumab use in patients with rheumatoid arthritis in Canada: 12-month results from an observational, noninterventional study. Rheumatol Ther 5:551\u2013565. https:\/\/doi.org\/10.1007\/s40744-018-0130-6","journal-title":"Rheumatol Ther"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06303-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06303-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06303-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:03:53Z","timestamp":1792263833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06303-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["6303"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06303-0","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"2 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this single-patient case report according to local institutional requirements. The report was prepared in accordance with the CARE guidelines and the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of this case report and the accompanying clinical data was obtained from the patient.","order":3,"name":"Ethics","label":"Patient consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work has not previously been presented or published as a congress abstract.","order":4,"name":"Ethics","label":"Related congress abstract publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No part of this case-based review has been copied from or published elsewhere. The scientific and clinical content, patient data, analyses, interpretations, and conclusions were generated by the authors and not by artificial intelligence. As stated in the Ethical AI Use disclosure, AI assistance was limited to language and editorial refinement, graph editing, and manuscript-structure review. All AI-assisted output was critically reviewed, verified, and approved by the authors.","order":5,"name":"Ethics","label":"<b>Disclaimer<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During manuscript preparation, the authors used OpenAI Codex (GPT-5; OpenAI) on July 31, August 1, September 3 and September 6 2026 for language editing, editorial refinement, manuscript structure review, and assistance with graph and table formatting and visual refinement without alteration of the underlying data. All AI-assisted output was critically reviewed and edited by the authors. The authors independently verified the scientific content, references, clinical data, and interpretations and approved the final manuscript. No AI tool was used to generate patient data, perform analyses, or independently formulate clinical conclusions. The authors take full responsibility for the accuracy and integrity of the final manuscript.","order":6,"name":"Ethics","label":"Ethical AI use","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external commercial editing agency or professional editing agent was involved in the preparation or revision of this manuscript.","order":7,"name":"Ethics","label":"External editing support","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"292"}}